From Bracco Research SA, Geneva, Switzerland,
BR14 is a new experimental ultrasound contrast agent, consisting of bubbles containing a high molecular weight filling gas enclosed by a flexible phospholipid monolayer shell a few nanometers thick.
This agent shows significant non-linear scattering and agent modification even at low insonation pressures, the detection pulses used did not destroy the contrast bubbles. The results obtained with HPD before the release burst show that the BR14 bubbles are efficient scatterers that can be modified and, thus, detected by low power insonation.

The company is a member of the Bracco Group, a highly innovative health care group and world leader in global integrated solutions for the diagnostic imaging field. The Bracco Group is headquartered in Milan, Italy. Its North American operations consist of Bracco Diagnostics and Bracco Research USA, both located in Princeton, New Jersey. Bracco Diagnostics is one of the fastest growing developers and marketers of diagnostic pharmaceuticals in North America, with products for various imaging applications, including Isovue® (iopamidol) X-ray contrast agent, ProHance®, (gadoteridol), MRI contrast agent, and nuclear medicine products.
Gadoteridol has been available in Europe and the USA for several years. Holder of the Marketing Authorization: Bracco International B.V. - Strawinskylaan 3051 - 1077 ZX Amsterdam The Netherlands. (Contact: Kirk Deeter, Phone: +NL-303-838-8708)

The Bracco Group is the world's leading provider of global diagnostic imaging solutions, with net sales of more than 1 billion euro, of which more than 64% from international sales; it has operations in 115 countries and about 3,500 employees, of whom more than 600 work in R&D. Bracco invests around 15% of its turnover in R&D and has a portfolio of 1,500 patents worldwide. The Bracco Group deploys an integrated approach to diagnostic imaging, with an offer that encompasses contrast media, its core business where it is one of the world's top players, biomedical equipment from Esaote, one of the world's primary producers of magnetic resonance and ultrasonographic medical equipment, contrast media delivery systems from Acist Medical Systems, a top US company in advanced contrast media injection systems, and medical application software from EBIT-AET and Singapore's Volume Interactions, the leading developer of advanced medical software. Bracco has formed a high-level international research network, whose three centers in Milan, Geneva and Princeton study and develop products for the latest-generation diagnostic techniques, from X-rays and computerized axial tomography to magnetic resonance and echo contrast.

Ultrasound Contrast Agents:

Brachytherapy is a radiation therapy in which radioactive material (radioisotopes) sealed in needles, seeds or wires is placed directly into or near a tumor. Brachytherapy uses ultrasound imaging to visualize the needles for accurate placement of the small seeds or pellets (capsules) directly into e.g., the prostate. Ultrasound imaging allows accurate planning, placement and implantation of the radiation sources. Implantation of the seeds is a minimally invasive procedure.
Radioactive seeds are inserted through the perineum skin (the area between the scrotum and the anus) into the prostate gland. With correct planning, the surgeon can implant the radiation sources for maximum benefits to effective cancer treatment.

See also EchoSeed™, Prostate Ultrasound, Thermotherapy, High Intensity Focused Ultrasound, Urologic Ultrasound, Transurethral Sonography.

Breast ultrasound (sonography or ultrasonography) it is an important tool in the characterization of breast lesions, detected with mammography or clinical breast examination. However, a breast sonogram is not approved by the U.S. Food and Drug Administration (FDA) as a screening tool for breast cancer and is used additional to a mammogram.
Ultrasound is useful in guiding needles for fine needle aspiration and core biopsies. Breast ultrasound has optimal contrast resolution, but it lacks the spatial resolution of conventional mammography and cannot provide as much detail as a mammogram image. In addition, ultrasound is unable to show tiny calcium deposits (microcalcifications) that are often early indications of breast cancer.

See also Biopsy, Interventional Ultrasound, Ultrasound Safety, Side Effect and Ultrasound Regulations.

Bristol-Myers Squibb Medical Imaging, Inc. was a wholly-owned subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), a pharmaceutical and related health care products company. Bristol-Myers Squibb sold its medical imaging business in 2007 to the private equity firm Avista Capital Partners for $525 million, as part of its effort to focus on its core pharmaceutical pipeline.
Formed in 1956 as New England Nuclear Corporation (NEN), the company grew to become a leader in the field of diagnostic imaging and later evolved through its transition from NEN to DuPont, followed by Bristol-Myers Squibb Medical Imaging (BMS), and finally named Lantheus Medical Imaging.